NFKB1 and neoplasm: αvβ3-ligand tetraiodothyroacetic acid (TET)-modified micelles have been shown to promote selective accumulation of the NF-κB inhibitor, celestrol, in primary tumours and lung metastases and to inhibit tumour growth and metastasis in a breast cancer mouse model to a greater extent than systemic delivery of celestrol alone [225].